Pricing
  1. US-listed companies
  2. HALOZYME THERAPEUTICS, INC.
  3. Financials
  4. Return on Assets

HALOZYME THERAPEUTICS, INC. (HALO)

Market cap
$7.9B
P/E ratio
SummaryFinancials
Period EndReturn on Assets (Million USD)YoY (%)
Dec 31, 202423.4+48.51%
Dec 31, 202315.8+14.80%
Dec 31, 202213.7-71.31%
Dec 31, 202147.8+112.25%
Dec 31, 202022.5-256.89%
Dec 31, 2019-14.4-14.17%
Dec 31, 2018-16.7-203.78%
Dec 31, 201716.1-134.68%
Dec 31, 2016-46.5+150.70%
Dec 31, 2015-18.5-63.70%
Dec 31, 2014-51.1-27.65%
Dec 31, 2013-70.6+32.14%
Dec 31, 2012-53.4

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat